This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Platzbecker U, Wermke M, Radke J, Oelschlaegel U, Seltmann F, Kiani A et al. Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leukemia 2012; 26: 381–389.
Yan CH, Liu DH, Liu KY, Xu LP, Liu YR, Chen H et al. Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Blood 2012; 119: 3256–3262.
Kern W, Voskova D, Schoch C, Hiddemann W, Schnittger S, Haferlach T . Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. Blood 2004; 104: 3078–3085.
Bacher U, Badbaran A, Fehse B, Zabelina T, Zander AR, Kröger N . Quantitative monitoring of NPM1 mutations provides a valid minimal residual disease parameter following allogeneic stem cell transplantation. Exp Hematol 2009; 37: 135–142.
Christopeit M, Ocheni S, Haferlach T, Miersch K, Zabelina T, Klyuchnikov E et al. Evaluation of BM cytomorphology after allo-SCT in patients with MDS. Bone Marrow Transplant 2013; 48: 465–466.
Christopeit M, Miersch K, Klyuchnikov E, Haferlach T, Binder M, Zabelina T et al. Evaluation of BM cytomorphology after allo-SCT in patients with AML. Bone Marrow Transplant 2012; 47: 1538–1544.
Chantepie SP, Salaun V, Parienti JJ, Truquet F, Macro M, Cheze S et al. Hematogones: a new prognostic factor for acute myeloblastic leukemia. Blood 2011; 117: 1315–1318.
Honebrink T, Dayton V, Burke MJ, Larsen K, Cao Q, Brunstein C et al. Impact of bone marrow hematogones on umbilical cord blood transplantation outcomes in patients with acute myeloid leukemia. Biol Blood Marrow Transplant 2012; 18: 930–936.
Shima T, Miyamoto T, Kikushige Y, Mori Y, Kamezaki K, Takase K et al. Quantitation of hematogones at the time of engraftment is a useful prognostic indicator in allogeneic hematopoietic stem cell transplantation. Blood 2012; 121: 840–848.
Christopeit M, Schütte V, Theurich S, Weber T, Grothe W, Behre G . Rituximab reduces the incidence of acute graft-versus-host disease. Blood 2009; 113: 3130–3131.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
TH declares part ownership of the MLL Munich Leukemia Laboratory GmbH. The remaining authors declare no conflict of interest.
Additional information
Author contributions
MC and UB designed the study, analysed data and wrote the manuscript. AH collected and analysed data; MB, TZ, FA, CH, TH, CB and NK analysed data. FA, CB and NK contributed to recruiting patients. All authors contributed to writing of the manuscript and the interpretation of data, and agreed to the final version of the manuscript. Data in this manuscript were in part assembled during the thesis (‘Dr med.’) work of AH.
Rights and permissions
About this article
Cite this article
Christopeit, M., Heiland, A., Binder, M. et al. Impact of physiological BM CD10+CD19+ B-cell precursors (haematogones) in the post-transplant period in patients with AML. Bone Marrow Transplant 48, 1257–1259 (2013). https://doi.org/10.1038/bmt.2013.34
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2013.34
This article is cited by
-
Clinical impact of hematogones on outcomes of allogeneic hematopoietic stem cell transplantation
Annals of Hematology (2015)
-
Relapse assessment following allogeneic SCT in patients with MDS and AML
Annals of Hematology (2014)